Showing results (41-50 of 63) with videos related to
Sort By:
Pageof 7
Inflammatory Bowel Diseases|November 7, 2023
Crohn's Disease Mortality and Ambient Air Pollution in New York CityAlexandra Feathers, Gina S Lovasi, Zoya Grigoryan, et al.Digestive Diseases and Sciences|July 23, 2020
Role of Hospital Teaching Status on Outcomes of Patients with Inflammatory Bowel Disease: A Nationwide AnalysisSachit Sharma, Simcha Weissman, Tej I Mehta, et al.Gastroenterology Research|January 21, 2022
Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19Keith Sultan, Laura Durbin, Richa Bhardwaj, et al.The Journal of Experimental Medicine|July 16, 2014
CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22Randy S Longman, Gretchen E Diehl, Daniel A Victorio, et al.Inflammatory Bowel Diseases|October 13, 2018
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficileDana J Lukin, Garrett Lawlor, David P Hudesman, et al.Journal of Clinical Neuromuscular Disease|April 28, 2012
Peripheral neuropathic symptoms in celiac disease and inflammatory bowel diseaseTing-Chin David Shen, Benjamin Lebwohl, Himanshu Verma, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 25, 2020
Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic EpicenterAmrita Sethi, Arun Swaminath, Melissa Latorre, et al.The American Journal of Gastroenterology|June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY ConsortiumParambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.Alimentary Pharmacology & Therapeutics|July 14, 2020
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's diseaseMatthew Bohm, Ronghui Xu, Yiran Zhang, et al.Pageof 7